90 related articles for article (PubMed ID: 2169340)
1. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker.
Gordon SG; Cross BA
Cancer Res; 1990 Oct; 50(19):6229-34. PubMed ID: 2169340
[TBL] [Abstract][Full Text] [Related]
2. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Rucińska M; Furman M; Skrzydlewski Z; Zaremba E
Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361
[TBL] [Abstract][Full Text] [Related]
3. New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors.
Mielicki WP; Tagawa M; Gordon SG
Thromb Haemost; 1994 Apr; 71(4):456-60. PubMed ID: 8052963
[TBL] [Abstract][Full Text] [Related]
4. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
5. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.
Allard WJ; Neaman IE; Elting JJ; Barnett TR; Yoshimura H; Fritsche HA; Yeung KK
Cancer Res; 1994 Mar; 54(5):1227-34. PubMed ID: 8118811
[TBL] [Abstract][Full Text] [Related]
6. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
9. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
10. [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer].
Kozuszko B; Skrzydlewski Z; Sulkowska M; Snarska J; Kozłowski M; Skrzydlewska E; Zalewski B
Pol Merkur Lekarski; 2001 Sep; 11(63):218-20. PubMed ID: 11761814
[TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic significance of cancer procoagulant activity in colorectal cancer].
Kozuszko B; Skrzydlewski Z; Famulski W
Pol Merkur Lekarski; 2000 Mar; 8(45):127-8. PubMed ID: 10870414
[TBL] [Abstract][Full Text] [Related]
14. Application of cancer procoagulant as an early detection tumor marker.
Kozwich DL; Kramer LC; Mielicki WP; Fotopoulos SS; Gordon SG
Cancer; 1994 Aug; 74(4):1367-76. PubMed ID: 8055461
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
[TBL] [Abstract][Full Text] [Related]
16. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
17. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.
Tong AW; Lee J; Stone MJ
Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911
[TBL] [Abstract][Full Text] [Related]
18. Cancer procoagulant--CP.
Rucińska M; Gacko M; Skrzydlewski Z
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():110-7. PubMed ID: 9337529
[TBL] [Abstract][Full Text] [Related]
19. New serum markers for small-cell lung cancer. II. The neural cell adhesion molecule, NCAM.
Vangsted A; Drivsholm L; Andersen E; Bock E
Cancer Detect Prev; 1994; 18(4):291-8. PubMed ID: 7982239
[TBL] [Abstract][Full Text] [Related]
20. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
